Development of gene therapy against HIV version 1
Research type
Research Study
Full title
Development of lentiviral therapy against HIV (by targeted TRIM-Cyclophilin gene insertion)
IRAS ID
140760
Contact name
Waseem Qasim
Contact email
Research summary
Human immunodeficiency virus (HIV) affects 34 million people worldwide, HIV infection leads to a decline in our immune cells and making us more susceptible to infections. Antiviral medications enable us to control HIV infection but does not lead to cure. Side effects from antiviral medications and development of drug resistance are some of the limitations of the treatment that we have today. The aim of this study is to develop new therapy that will ultimately lead to the cure of HIV. We hope to develop a therapy that can integrate anti-HIV genes into patients’ immune cells, rendering patients resistant to HIV.
In order to develop this new therapy we require blood from patients with HIV to assess the efficacy of the new therapy. We open this study to patients with HIV at the Great Ormond Street Hospital over a period of 3 years. Participants are required to give a small amount of blood, and this can be done with the routine blood tests. This is a laboratory proof of concept study, these genetically modified cells will never be put back into Humans.REC name
Yorkshire & The Humber - Leeds East Research Ethics Committee
REC reference
14/YH/0105
Date of REC Opinion
9 May 2014
REC opinion
Further Information Favourable Opinion